The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000749303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
13/11/2025
Date registered
Help: Date registered
23/06/2026
Date last updated
Help: Date last updated
23/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A randomised controlled trial in adults with obesity to evaluate the effects of tirzepatide-induced weight loss, with and without structured exercise, on metabolic, immunological, and imaging biomarkers of systemic and brain inflammation.
Scientific title
A randomised controlled trial in adults with obesity to evaluate the effects of tirzepatide-induced weight loss, with and without structured exercise, on metabolic, immunological, and imaging biomarkers of systemic and brain inflammation.
Additional trial identifiers [1] 315874 0
None.
Universal Trial Number (UTN)
Trial acronym
TIREX: TIRzepatide and EXercise for Reducing Neuroinflammation
Related trial records

Health condition
Health condition(s) studied:
Obesity 339635 0
Neuroinflammation 339636 0
Condition category
Condition code
Diet and Nutrition 335879 335879 0 0
Obesity
Neurological 335880 335880 0 0
Other neurological disorders
Metabolic and Endocrine 335881 335881 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
TIRZEPATIDE
Eligible participants will be individuals who are opportunistically recruited, having been prescribed or considering treatment with tirzepatide for weight management. The safety and appropriateness of tirzepatide treatment will have been determined by the participant’s prescribing clinician prior to study inclusion, with dosing and continuation managed as part of routine clinical care.

Tirzepatide is administered as a once-weekly subcutaneous injection, typically initiated at 2.5 mg and titrated in 2.5 mg increments each month up to a maximum of 15 mg weekly, with the most common maintenance dose being 5 mg once weekly. As participants are recruited following clinical prescription, they may be on varying doses depending on their stage of dose escalation, and treatment will continue for up to 6 months in line with the study duration.

Participant adherence, including current dose, missed doses, treatment changes, and any side effects, will be monitored using a standardised questionnaire during regular phone or in-person follow-up.

The study duration will be 6 months. Safety blood tests will be performed at baseline and at the end of the study, and a medical assessment will be conducted as part of the screening process. Participants who discontinue tirzepatide during the study will be invited to continue participation, with all treatment changes recorded for analysis.

EXERCISE INTERVENTION
Following baseline assessments and commencement of tirzepatide, participants randomised to the intervention group will undertake a supervised physical activity program for 12 weeks. This program will be individualised based on each participant’s baseline activity levels and physical capacity.

The goal is for participants to work up to the below physical activity targets during the supervised period:
(1) At least 150 minutes of moderate-intensity aerobic physical activity per week, 55–80% peak heart rate (monitored via Fitbit), 4–6 on Borg's modified Rating of Perceived Exertion (RPE) scale, involving large muscle groups, over 3 to 5 days per week.
(2) Moderate-to-high intensity resistance exercises, 10–15 repetitions of each exercise, 4–6 on Borg's RPE scale, targeting large muscle groups, over 2 to 3 days per week.

Aerobic
All aerobic sessions will include a 3-minute light intensity warm-up and 2-minute cool down, equivalent to an RPE of 1-3 out of 10. Aerobic exercises will be done via a treadmill, cycle ergometer, or land-based walking as appropriate. Exercise intensity will be individualised based on each participant’s baseline testing (e.g., HRpeak or peak power output) and monitored using the RPE scale and heart rate monitors (Fitbit and/or Polar devices).

Resistance
All strength sessions will be completed with a 5-minute cool down including static stretches and breathing. The resistance program will include 6 to 8 compound exercises focusing on major muscle groups to improve muscle strength and muscle mass such as squats, lunges, modified push-ups, etc. The dosage will include 1 to 3 sets of 8 to 15 repetitions performed at 55-70% of their 1 repetition maximum at baseline, with 1-2-minute rest between sets. The intensity and volume will progressively increase over the course of the 12-week program as tolerated. Technique will be closely monitored, and participants will be encouraged to perform the exercises with control.

Participants will attend 2–3 supervised sessions per week (approximately 1 hour each) with an accredited exercise physiologist (AEP). Sessions may be delivered individually or in small groups (up to three participants), either in person or via telehealth. During the supervised phase, any prescribed home-based exercises will be supported using the Physitrack platform.

Following the supervised period, participants will continue with an individualised home-based exercise program for the remainder of the study (up to 6 months). Exercise adherence and progression will be supported and monitored using Fitbit and the Physitrack platform, which will be used by the AEP to adjust exercise programs. Regular follow-up will be conducted via phone, email, or telehealth. Participants who are not meeting their prescribed exercise targets may be contacted and encouraged to attend additional supervised sessions where appropriate.
Intervention code [1] 332476 0
Prevention
Intervention code [2] 332477 0
Treatment: Other
Intervention code [3] 333787 0
Behaviour
Description of the comparator or control
Participants in the control group will receive tirzepatide as prescribed by their usual clinician, consistent with the intervention group. Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing (typically 2.5–15 mg), escalation, and treatment duration of up to 6 months determined by the prescribing clinician according to individual participant needs.

Participant adherence, including current dose, missed doses, treatment changes, and any side effects, will be monitored using a standardised questionnaire during regular phone or in-person follow-up.

Control participants will not receive the supervised exercise program delivered to the intervention group. However, they will be provided with a Fitbit device and will receive monthly phone follow-up from an AEP. These interactions will provide general information based on current evidence and guidelines for exercise and physical activity in individuals using tirzepatide but will not include personalised exercise prescription or supervised training.

Control participants will follow the same schedule of study visits and assessments as those in the intervention arm.
Control group
Active

Outcomes
Primary outcome [1] 343395 0
Mean between-group difference in restricted fraction (a measure of neuroinflammation-related cellularity) in the hippocampus.
Timepoint [1] 343395 0
End of study (6 months after commencing tirzepatide).
Primary outcome [2] 344901 0
Mean between-group difference in fibre fraction (a marker of axonal integrity), in the hippocampus.
Timepoint [2] 344901 0
End of study (6 months after commencing intervention).
Primary outcome [3] 345097 0
Mean between-group difference in hindered fraction (a marker of tissue oedema) in the hippocampus.
Timepoint [3] 345097 0
End of study (6 months after commencing intervention).
Secondary outcome [1] 460442 0
Mean between-group difference in DBSI-derived metrics (restricted, fibre, and hindered fractions) across other brain regions. This will be assessed as a composite outcome.
Timepoint [1] 460442 0
End of study (6 months after commencing intervention).
Secondary outcome [2] 460443 0
Within-group change from baseline in DBSI-derived metrics (restricted, fibre, and hindered fractions) across brain regions. This will be assessed as a composite outcome.
Timepoint [2] 460443 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [3] 460444 0
Mean between-group difference in hippocampal volume between intervention and control groups.
Timepoint [3] 460444 0
End of study (6 months after commencing intervention).
Secondary outcome [4] 460445 0
Mean between-group difference in regional brain volumes (including cortical and subcortical regions) between intervention and control groups.
Timepoint [4] 460445 0
End of study (6 months after commencing intervention).
Secondary outcome [5] 460446 0
Within-group change from baseline in brain volumes across regions.
Timepoint [5] 460446 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [6] 460447 0
Neuroinflammatory fluid biomarkers; glial fibrillary acidic protein (GFAP).
Timepoint [6] 460447 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [7] 460448 0
Neuroinflammatory fluid biomarkers; neurofilament light chain (Nfl).
Timepoint [7] 460448 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [8] 460449 0
Neuroinflammatory fluid biomarkers; soluble triggering receptor expressed on myeloid cells 2 (sTREM2).
Timepoint [8] 460449 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [9] 460450 0
Neuroinflammatory fluid biomarkers; chitinase-3-like protein 1 (YKL-40).
Timepoint [9] 460450 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [10] 460451 0
body mass index (BMI; kg/m2) via measurement of height (cm) and body mass (kg).
Timepoint [10] 460451 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [11] 460452 0
Composite metabolic control.
Timepoint [11] 460452 0
Baseline and 6 months after commencing intervention.
Secondary outcome [12] 460453 0
Fluid inflammatory markers; C-reactive protein (CRP).
Timepoint [12] 460453 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [13] 460454 0
Fluid inflammatory markers; tumour necrosis factor-alpha (TNF-alpha).
Timepoint [13] 460454 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [14] 460455 0
Fluid inflammatory markers; interleukin-6 (IL-6).
Timepoint [14] 460455 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [15] 460456 0
Hormonal control; leptin.
Timepoint [15] 460456 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [16] 460457 0
Hormonal control; adiponectin.
Timepoint [16] 460457 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [17] 460459 0
Hormonal control; cortisol.
Timepoint [17] 460459 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [18] 460460 0
Peripheral immune cell populations e.g., macrophages.
Timepoint [18] 460460 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [19] 460461 0
Peripheral blood pressures (mmHg).
Timepoint [19] 460461 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [20] 460462 0
Arterial stiffness.
Timepoint [20] 460462 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [21] 460463 0
Autonomic function; heart rate variability (HRV; ms2): low frequency (LF) and high frequency (HF). This will be assessed as a composite outcome.
Timepoint [21] 460463 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [22] 460464 0
Aerobic capacity.
Timepoint [22] 460464 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [23] 460465 0
Strength capacity.
Timepoint [23] 460465 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [24] 460466 0
Whole body fat-free mass (%).
Timepoint [24] 460466 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [25] 460467 0
Bone mineral density (g/cm2) of the hip.
Timepoint [25] 460467 0
Baseline and 6 months after commencing intervention.
Secondary outcome [26] 460470 0
Liver fat percentage.
Timepoint [26] 460470 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [27] 460472 0
Diet quantity and quality. This will be assessed as a composite outcome.
Timepoint [27] 460472 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [28] 460473 0
Gut microbiome.
Timepoint [28] 460473 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [29] 460474 0
Neuropsychological; visuospatial skills, visuomotor functioning, and processing speed. This will be assessed as a composite outcome.
Timepoint [29] 460474 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [30] 460475 0
Neuropsychological; language.
Timepoint [30] 460475 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [31] 460476 0
Neuropsychological; executive functioning.
Timepoint [31] 460476 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [32] 460477 0
Neuropsychological; verbal learning and memory. This will be assessed as a composite outcome.
Timepoint [32] 460477 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [33] 460479 0
Neuropsychological; processing speed and sustained attention. This will be assessed as a composite outcome.
Timepoint [33] 460479 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [34] 460480 0
Neuropsychological; predicting intellectual and memory performance. This will be assessed as a composite outcome.
Timepoint [34] 460480 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [35] 460481 0
Neuropsychological; sustained attention.
Timepoint [35] 460481 0
Baseline and end of study (6 months after commencing intervention).
Secondary outcome [36] 461898 0
Arterial stiffness, central blood pressures (mmHg).
Timepoint [36] 461898 0
Baseline, 3, and 6 months after commencing intervention.
Secondary outcome [37] 461901 0
exploratory outcomes will also be assessed at baseline and end of study (6 months after commencing intervention).
Timepoint [37] 461901 0
Baseline and 6 months after commencing intervention.

Eligibility
Key inclusion criteria
35-65 years of age.
Eligible for treatment with tirzepatide and planning to take tirzepatide.
Have obesity (BMI greater than or equal to 30 kg/m²).
Must have access to Wi-Fi/internet and a device able to run the Fitbit app.
Willingness to provide informed consent and willingness to participate and comply with the study requirements.
Minimum age
35 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Unable to safely undergo MRI (e.g., due to size limitations, claustrophobia, or non-MRI-compatible implanted devices).
History or clinical manifestation of any other significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, immune, hepatic, renal, urologic, muscular, and joint disorders, or cancer that, in the opinion of the investigator, would make the candidate ineligible for the study. For example, significant joint pain could interfere with adherence to the exercise program.
Have moderate cognitive impairment as assessed by the Montreal Cognitive Assessment (MoCA) i.e., total score less than 18.
Inability to exercise via supine ergometer.
Psychiatric or behavioral problems (e.g., history of drug and alcohol abuse, eating disorder).
Breastfeeding or pregnant women, or those intending to become pregnant before the scheduled end of the intervention.
Unwilling to be assigned at random to the exercise or control intervention.
Unwilling or unable to adhere to the rigors of the exercise intervention or evaluation schedule over the entire one-year period.
Concurrent participation in any other interventional study.
Had been taking another GLP-1 or GIP receptor agonist in the month prior to commencing tirzepatide.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be randomised using computer generated random numbers, via a web-based randomisation system, i.e., central randomisation by computer. The statistician will design the randomisation schedule.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
1:1 simple randomisation via REDCap, schedule created by a blinded statistician.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29347 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 29348 0
Camden Hospital - Camden
Recruitment postcode(s) [1] 45665 0
2050 - Camperdown
Recruitment postcode(s) [2] 45666 0
2570 - Camden

Funding & Sponsors
Funding source category [1] 320466 0
Government body
Name [1] 320466 0
National Health and Medical Research Council
Country [1] 320466 0
Australia
Primary sponsor type
University
Name
The University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 323085 0
None
Name [1] 323085 0
Address [1] 323085 0
Country [1] 323085 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319017 0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Ethics committee address [1] 319017 0
Ethics committee country [1] 319017 0
Australia
Date submitted for ethics approval [1] 319017 0
14/04/2026
Approval date [1] 319017 0
14/04/2026
Ethics approval number [1] 319017 0
X25-0140

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 145998 0
Prof Laura Piccio
Address 145998 0
Level 5 West D17 – Education and Research Hub The Charles Perkins Centre Camperdown The University of Sydney NSW 2006
Country 145998 0
Australia
Phone 145998 0
+61 2 8627 7413
Fax 145998 0
Email 145998 0
Contact person for public queries
Name 145999 0
Jessica Raiti
Address 145999 0
Level 5 West D17 – Education and Research Hub The Charles Perkins Centre Camperdown The University of Sydney NSW 2006
Country 145999 0
Australia
Phone 145999 0
+61 2 8627 7413
Fax 145999 0
Email 145999 0
Contact person for scientific queries
Name 146000 0
Laura Piccio
Address 146000 0
Level 5 West D17 – Education and Research Hub The Charles Perkins Centre Camperdown The University of Sydney NSW 2006
Country 146000 0
Australia
Phone 146000 0
+61 2 8627 7413
Fax 146000 0
Email 146000 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• Non-identifiable participant data will be shared based upon the research proposal and subsequent discretion of the Principal Investigator. This will include all data.

What types of analyses could be done with individual participant data?
• This will depend on the research proposal and discretion of the Principal Investigator.

When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Contact the Principal Investigator by email ([email protected]).


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.